<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02502071</url>
  </required_header>
  <id_info>
    <org_study_id>15-0541</org_study_id>
    <nct_id>NCT02502071</nct_id>
  </id_info>
  <brief_title>Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 Diabetes</brief_title>
  <acronym>Alk-UA</acronym>
  <official_title>Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 DiabetesL a Open-label Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado Denver School of Medicine Barbara Davis Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado Denver School of Medicine Barbara Davis Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether alkalinization of urine uric acid by 2
      doses of sodium bicarbonate (1950mg) over 24-hours reduces precipitation and crystallization
      of urine uric acid over in adults with type 1 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetic nephropathy is characterized not only by glomerular disease but also
      tubulointerstitial injury. The tubular changes associated with diabetic nephropathy, include
      basement membrane thickening, tubular hypertrophy, epithelial-mesenchymal transition,
      glycogen accumulation and interstitial inflammation. Although glomerular changes has received
      significantly more attention from researchers and clinicians than tubulointerstitial changes
      in diabetes, tubular injury is known to associate better with renal function than glomerular
      injury. In fact, tubular proteinuria may precede microalbuminuria with type 1 diabetes,
      suggesting that tubular damage may be induced earlier than glomerular injury in the course of
      diabetic nephropathy.

      Serum uric acid (SUA) is lower in adolescents and adults with type 1 diabetes compared to
      non-diabetic peers. Despite lower levels SUA remains an important risk factor for diabetic
      nephropathy in type 1 diabetes, with a large clinical trial underway examining the ability of
      allopurinol to prevent early renal loss. Several mechanisms have been proposed to explain the
      lower levels of SUA in type 1 diabetes including glucosuria induced uricosuria leading to
      spilling of urine uric acid (UUA) and lowering of SUA, and the notion that intracellular uric
      acid (IUA) and/ or UUA rather than SUA may be responsible for the development of
      complications. Animal studies have demonstrated that blocking uric acid production protects
      the kidney from tubulointerstitial injury, which suggests a causal role for uric acid in the
      development of diabetic tubular injury. Relative dehydration, secondary to glucosuria,
      exercise or inadequate liquid intake, may lead to concentrated and acidic urine, which may
      cause UUA to precipitate and crystallize in type 1 diabetes. The UUA precipitation and
      crystallization is thought to induce inflammation and injury of the tubules with possible
      retrograde glomerular injury. Moreover, it was recently shown that UUA promoted apoptosis in
      human proximal tubular cells by oxidative stress and activation of NADPH Oxidase NOX 4.

      Oral alkali replacements are readily available, safe and include the following formulations
      sodium bicarbonate, BiCitra (sodium citrate and citric acid), PolyCitra (citric acid, sodium
      citrate, and potassium citrate), polycitra-K (potassium citrate and citric acid). In contrast
      to sodium bicarbonate, citrate is converted to bicarbonate in the liver and thus this
      conversion is affected by liver disease. Usual adult doses for urinary alkalinization are 325
      to 2000 mg orally 1 to 4 times a day. One gram provides 12 mEq (mmoL) each of sodium and
      bicarbonate, and is titrated to a goal of urine pH of 8.0. In a prospective open-label trial
      4 g of sodium bicarbonate was administered orally 3 times daily to 9 healthy volunteers for
      24 hours, and after 10 hours all participants had a urine pH ≥ 7 and after 20 hours all
      participants had urine pH ≥ 8. No adverse effects or abnormal blood results were documented
      during the 24-hour follow-up. Urinary alkalinization should solubilize UUA thereby increasing
      the concentration of uric acid in urine and decreasing precipitation and crystallization of
      UUA. It is unknown whether alkalinization of urine reduces UUA precipitation and
      crystallization in type 1 diabetes.

      With diabetic nephropathy being the leading cause of end-stage renal disease in the Western
      world, it is critical to develop a better understanding of the determinants of risk and
      progression of early diabetic nephropathy, to improve outcomes in patients with type 1
      diabetes. UUA is a particularly attractive therapeutic target due to the potential to reduce
      tubular injury with sodium bicarbonate. Accordingly, the investigators propose a pilot
      experimental study examining the effect of urine alkalinization with oral sodium bicarbonate
      on UUA precipitation and crystallization in adults with type 1 diabetes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Urine Uric Acid Concentration (Increased Solubility) by Assay</measure>
    <time_frame>Day 1 (pre-therapy) and Day 2 (post-therapy)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Number of Participants With Urine Uric Acid Precipitation by Polarized Microscopy</measure>
    <time_frame>Day 1 (pre-therapy) and Day 2 (post-therapy)</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Type 1 Diabetes</condition>
  <condition>Diabetic Nephropathy</condition>
  <condition>Diabetic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Sodium Bicarbonate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive 2 doses of 1950mg Sodium Bicarbonate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sodium bicarbonate</intervention_name>
    <description>All participants will receive 2 doses of 1950mg sodium bicarbonate</description>
    <arm_group_label>Sodium Bicarbonate</arm_group_label>
    <other_name>NaHCO3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults (aged 18-45 years) with type 1 diabetes

          -  Participants must be able to be fasting prior to study visit and give informed
             consent.

        Exclusion Criteria:

          -  Non-type 1 diabetes

          -  History of eGFR &lt;60 ml/min/1.73m2 or microalbuminuria or greater

          -  History of hypocalcemia or at risk of hypocalcemia

          -  Taking allopurinol or uric acid altering medications

          -  Ketogenic diet

          -  Ketonuria

          -  Taking phosphorus binders (e.g. sevelamer)

          -  Pregnant or breastfeeding

          -  Taking the following medications which may interact with sodium bicarbonate (e.g.
             phentermine, pseudoephedrine, antifungal medication, cephalosporin antibiotics [e.g.
             Keflex], tetracycline antibiotics [e.g. doxycycline], steroids or lithium)

          -  Taking SGLT-2 inhibitors

          -  Taking blood pressure medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Barbara Davis Center for Diabetes</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Drummond K, Mauer M; International Diabetic Nephropathy Study Group. The early natural history of nephropathy in type 1 diabetes: II. Early renal structural changes in type 1 diabetes. Diabetes. 2002 May;51(5):1580-7.</citation>
    <PMID>11978659</PMID>
  </reference>
  <reference>
    <citation>Gilbert RE, Cooper ME. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int. 1999 Nov;56(5):1627-37. Review.</citation>
    <PMID>10571771</PMID>
  </reference>
  <reference>
    <citation>Ginevri F, Piccotti E, Alinovi R, DeToni T, Biagini C, Chiggeri GM, Gusmano R. Reversible tubular proteinuria precedes microalbuminuria and correlates with the metabolic status in diabetic children. Pediatr Nephrol. 1993 Feb;7(1):23-6.</citation>
    <PMID>8439475</PMID>
  </reference>
  <reference>
    <citation>Bjornstad P, Snell-Bergeon JK, McFann K, Wadwa RP, Rewers M, Rivard CJ, Jalal D, Chonchol MB, Johnson RJ, Maahs DM. Serum uric acid and insulin sensitivity in adolescents and adults with and without type 1 diabetes. J Diabetes Complications. 2014 May-Jun;28(3):298-304. doi: 10.1016/j.jdiacomp.2013.12.007. Epub 2013 Dec 27.</citation>
    <PMID>24461546</PMID>
  </reference>
  <reference>
    <citation>Bjornstad P, Lanaspa MA, Ishimoto T, Kosugi T, Kume S, Jalal D, Maahs DM, Snell-Bergeon JK, Johnson RJ, Nakagawa T. Fructose and uric acid in diabetic nephropathy. Diabetologia. 2015 Sep;58(9):1993-2002. doi: 10.1007/s00125-015-3650-4. Epub 2015 Jun 7. Review.</citation>
    <PMID>26049401</PMID>
  </reference>
  <reference>
    <citation>Bjornstad P, Maahs DM, Rivard CJ, Pyle L, Rewers M, Johnson RJ, Snell-Bergeon JK. Serum uric acid predicts vascular complications in adults with type 1 diabetes: the coronary artery calcification in type 1 diabetes study. Acta Diabetol. 2014 Oct;51(5):783-91. doi: 10.1007/s00592-014-0611-1. Epub 2014 Jun 15.</citation>
    <PMID>24929955</PMID>
  </reference>
  <reference>
    <citation>Maahs DM, Caramori L, Cherney DZ, Galecki AT, Gao C, Jalal D, Perkins BA, Pop-Busui R, Rossing P, Mauer M, Doria A; PERL Consortium. Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study. Curr Diab Rep. 2013 Aug;13(4):550-9. doi: 10.1007/s11892-013-0381-0. Review.</citation>
    <PMID>23649945</PMID>
  </reference>
  <reference>
    <citation>Lytvyn Y, Škrtić M, Yang GK, Yip PM, Perkins BA, Cherney DZ. Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. Am J Physiol Renal Physiol. 2015 Jan 15;308(2):F77-83. doi: 10.1152/ajprenal.00555.2014. Epub 2014 Nov 5.</citation>
    <PMID>25377916</PMID>
  </reference>
  <reference>
    <citation>Schepers MS, van Ballegooijen ES, Bangma CH, Verkoelen CF. Crystals cause acute necrotic cell death in renal proximal tubule cells, but not in collecting tubule cells. Kidney Int. 2005 Oct;68(4):1543-53.</citation>
    <PMID>16164631</PMID>
  </reference>
  <reference>
    <citation>Ryu ES, Kim MJ, Shin HS, Jang YH, Choi HS, Jo I, Johnson RJ, Kang DH. Uric acid-induced phenotypic transition of renal tubular cells as a novel mechanism of chronic kidney disease. Am J Physiol Renal Physiol. 2013 Mar 1;304(5):F471-80. doi: 10.1152/ajprenal.00560.2012. Epub 2013 Jan 2.</citation>
    <PMID>23283992</PMID>
  </reference>
  <reference>
    <citation>Verzola D, Ratto E, Villaggio B, Parodi EL, Pontremoli R, Garibotto G, Viazzi F. Uric acid promotes apoptosis in human proximal tubule cells by oxidative stress and the activation of NADPH oxidase NOX 4. PLoS One. 2014 Dec 16;9(12):e115210. doi: 10.1371/journal.pone.0115210. eCollection 2014.</citation>
    <PMID>25514209</PMID>
  </reference>
  <reference>
    <citation>Cohen B, Laish I, Brosh-Nissimov T, Hoffman A, Katz LH, Braunstein R, Sagi R, Michael G. Efficacy of urine alkalinization by oral administration of sodium bicarbonate: a prospective open-label trial. Am J Emerg Med. 2013 Dec;31(12):1703-6. doi: 10.1016/j.ajem.2013.08.031. Epub 2013 Sep 20.</citation>
    <PMID>24055481</PMID>
  </reference>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>July 16, 2015</study_first_submitted>
  <study_first_submitted_qc>July 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2015</study_first_posted>
  <results_first_submitted>October 18, 2018</results_first_submitted>
  <results_first_submitted_qc>November 17, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 20, 2018</results_first_posted>
  <last_update_submitted>November 17, 2018</last_update_submitted>
  <last_update_submitted_qc>November 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Colorado Denver School of Medicine Barbara Davis Center</investigator_affiliation>
    <investigator_full_name>Petter Bjornstad</investigator_full_name>
    <investigator_title>Fellow</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 24, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/71/NCT02502071/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sodium Bicarbonate</title>
          <description>All participants will receive 2 doses of 1950mg Sodium Bicarbonate
sodium bicarbonate: All participants will receive 2 doses of 1950mg sodium bicarbonate</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sodium Bicarbonate</title>
          <description>All participants will receive 2 doses of 1950mg Sodium Bicarbonate
sodium bicarbonate: All participants will receive 2 doses of 1950mg sodium bicarbonate</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.6" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type 1 Diabetes Duration</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.2" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Urine Uric Acid Concentration (Increased Solubility) by Assay</title>
        <time_frame>Day 1 (pre-therapy) and Day 2 (post-therapy)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sodium Bicarbonate</title>
            <description>All participants will receive 2 doses of 1950mg Sodium Bicarbonate
sodium bicarbonate: All participants will receive 2 doses of 1950mg sodium bicarbonate</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Urine Uric Acid Concentration (Increased Solubility) by Assay</title>
          <units>mg/dl</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (pre-therapy)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.81" lower_limit="18.93" upper_limit="29.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 (post-therapy)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.30" lower_limit="17.63" upper_limit="28.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Number of Participants With Urine Uric Acid Precipitation by Polarized Microscopy</title>
        <time_frame>Day 1 (pre-therapy) and Day 2 (post-therapy)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sodium Bicarbonate</title>
            <description>All participants will receive 2 doses of 1950mg Sodium Bicarbonate
sodium bicarbonate: All participants will receive 2 doses of 1950mg sodium bicarbonate</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Number of Participants With Urine Uric Acid Precipitation by Polarized Microscopy</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (pre-therapy)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 (post-therapy)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected while the participant was in the trial (24-36 hours)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sodium Bicarbonate</title>
          <description>All participants will receive 2 doses of 1950mg Sodium Bicarbonate
sodium bicarbonate: All participants will receive 2 doses of 1950mg sodium bicarbonate</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <description>Patient asked to fast and had a low serum blood glucose (31 mg/dl) with a normal point of care glucose (90 mg/dl) in clinic. Patient contacted upon receipt of serum glucose results. Patient asymptomatic with a normal glucose at the time of call.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Petter Bjornstad, Assistant Professor</name_or_title>
      <organization>University of Colorado School of Medicine</organization>
      <phone>7207774659</phone>
      <email>petter.bjornstad@childrenscolorado.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

